Disclosure {#j_raon-2019-0015_s_010}
==========

No potential conflicts of interest were disclosed.

Introduction {#j_raon-2019-0015_s_001}
============

Colorectal cancer (CRC) is an important cause of death as well as decreased quality of life. Worldwide, CRC is the third most commonly diagnosed malignancy and the fourth most common cause of death.[@j_raon-2019-0015_ref_001] The incidence of CRC is higher in the developed countries.[@j_raon-2019-0015_ref_002] The 5-year and 10-year survival rates of operable and localized colorectal cancer are 60% and 50%, respectively.[@j_raon-2019-0015_ref_003]

In Slovenia, 11,269 patients (56% men, 44% women) with CRC were still alive at the end of 2015. CRC is the fourth most commonly diagnosed malignancy among Slovenian cancer patients.[@j_raon-2019-0015_ref_004] In 2015, 1,356 patients were diagnosed with CRC (58% men, 42% women). Colon cancer was found most frequently (63%), followed by cancer of the rectum and rectosigmoid junction. (37%).[@j_raon-2019-0015_ref_004]

Impaired health-related quality of life (QoL) in CRC patients may result from the disease itself and/or treatment.[@j_raon-2019-0015_ref_005] It can be described as psychophysical, functional, and emotional disruption or social impairment.[@j_raon-2019-0015_ref_006],[@j_raon-2019-0015_ref_007] Standardized questionnaires are used to evaluate QoL in cancer patients.[@j_raon-2019-0015_ref_008] The most commonly used questionnaire for evaluating QoL in oncology is the EORTC QLQ-C30 questionnaire, launched by the European Organisation for Research and Treatment of Cancer (EORTC).[@j_raon-2019-0015_ref_009] It has been translated into many languages, including Slovenian.[@j_raon-2019-0015_ref_010] The reference values of the EORTC QLQ-C30 questionnaire for the general Slovenian population have already been obtained and published.[@j_raon-2019-0015_ref_011] Moreover, the EORTC developed the colorectal QoL module EORTC QLQ-CR29, which has been used as an addition to the EORTC QLQ-C30 to evaluate QoL in CRC patients.[@j_raon-2019-0015_ref_012]

The aim of this study was to evaluate QoL in CRC patients after colorectal surgery and to compare the results with the reference data from the general Slovenian population.

Patients and methods {#j_raon-2019-0015_s_002}
====================

Patients {#j_raon-2019-0015_s_002_s_001}
--------

QoL was evaluated for patients with CRC, stages I--IV, with and without metastatic disease, operated on at the Abdominal Surgery Department of the Ljubljana University Medical Center from January 1^st^, 2016 to January 31^st^, 2017. Patients still alive on January 1^st^, 2018 were included. A patient chart review was performed. A total of 413 patients met the inclusion criteria and were sent the questionnaire; of these, 197 patients (116 male, 81 female) returned the questionnaire. Patients at least one year and no more than two years from the initial operation were included in the study.

Questionnaires {#j_raon-2019-0015_s_002_s_002}
--------------

For the purpose of this study, the standardized questionnaires EORTC QLQ-C30 and QLQ-CR29 were utilized. The questionnaires were translated into Slovenian.

The EORTC QLQ-C30 questionnaire consists of three scoring scales that grade function, symptoms, and global health. The scales include one or more questions. Each question has four response options from 1 = not at all to 4 = very much. A higher score corresponds to a poorer result and more symptoms present. On the other hand, global health status is categorized with seven-point scoring scale on which a higher score corresponds to greater well-being and higher quality of life.

The EORTC QLQ-CR29 questionnaire consists of two scoring scales that grade function and symptoms, and it has specifically been used to assess QoL in CRC patients. As for the EORTC QLQ-C30, the responses range from 1 to 4 and a higher score defines a poorer outcome, with exception of the response for sexual interest, for which a higher score correlates with a better result.

Statistical analysis {#j_raon-2019-0015_s_002_s_003}
--------------------

Because the scoring scales consist of one or more questions (anxiety on the EORTC QLQ-CR29 and cognitive functions on the EORTC-CR29), a raw score (RS) was calculated for each scoring scale. Linear transformation was used to standardize the RS and the transformed recorded answers into dimensions ranging from 0 to 100. Higher scores on functional scoring scales correlated with better functions in patients and, on the other hand, higher scores on symptom scoring scales correlated with poorer outcomes. For the linear transformation, the following formulas were applied:

1.  For functional scoring scales: S = ;

2.  For symptom scoring scales: S = ;

3.  For global health-status: S.

The numerical variables were represented by means and standard deviations. The differences between numerical variables were tested using Student's *t*-test. For the purpose of the statistical analysis, patients were divided into two age groups according to the reported median age of 73 years. First group included patients from 39 to 73 years and the second group patients from 74 to 92 years. The association between age groups and sexes was tested using the Mann--Whitney test. A *p*-value \< 0.05 was considered statistically significant. Statistical analyses were performed using SPSS software (IBM Corp., version 24.0 Armonk, NY).

Approval for the study was obtained from the Medical Ethics Committee of the Republic of Slovenia, the Protocol Review Board (MZ 0120-48/2018-6). Written consent from all patients included was provided prior to study enrollment.

Results {#j_raon-2019-0015_s_003}
=======

A total of 413 patients received the questionnaire, and the response rate was 47.7% (197 patients).

Characteristics of the study population are shown in [Table 1](#j_raon-2019-0015_tab_001){ref-type="table"}.

###### 

Characteristics of the study population

                                      Responders n 197   Non-responders n 216   p-value
  ----------------------------------- ------------------ ---------------------- ---------
  Median age (IQR)                    72 (62--79)        74 (65--81)            0.016
  **Sex**                                                                       
  Male (%)                            116 (58.9)         133(61.5)              0.603
  Female (%)                          81 (41.1)          83 (38.5)              
  **Complications**                                                             
  Not reported                        175 (88.8)         150 (69.4)             \<0.001
  Severe^\*^ (%)                      15 (7.6)           32 (14.8)              
  **Operation**                                                                 
  Right hemicolectomy                 80 (40.6)          101 (46.8)             0.208
  Extended right hemicolectomy        8(4.1)             17(7.9)                0.033
  Left hemicolectomy                  26 (13.2)          19 (8.8)               0.152
  Hartmann's procedure                10 (5.1)           14 (6.5)               0.542
  Rectosigmoid resection              4 (2)              8 (3.7)                0.312
  Low anterior resection              13 (6.6)           8 (3.7)                0.181
  Sigmoid resection                   46 (23.4)          38 (17.6)              0.147
  Subtotal colectomy                  2 (1)              5 (2.3)                0.298
  Total colectomy                     5 (2.5)            3 (1.4)                0.396
  Segmental resections of the colon   4(2)               2(0.9)                 0.007
  Other procedures                    1 (0.5)            2 (0.9)                0.613

Clavien--Dindo classification 3 to 5; IQR = interquartile range; n = number of patients

EORTC QLQ-C3 Scoring scale {#j_raon-2019-0015_s_003_s_001}
--------------------------

When the average scores of the EORTC QLQ-C30 in the general Slovenian population and in patients with CRC were compared, statistically significant differences in QoL were detected. Physical, role, cognitive, and social functioning scores were significantly lower in patients with CRC compared to the general population. Compared to the general population, CRC patients more often experienced symptoms as constipation and diarrhea. Moreover, compared to general population, financial difficulties were also more often reported by the CRC patients. No other statistically significant differences were detected between CRC patients and the general population ([Table 2](#j_raon-2019-0015_tab_002){ref-type="table"}).[@j_raon-2019-0015_ref_011]

###### 

Comparison of the scores for all scales of the EORTC QLQ-C30 between CRC patients and the general Slovenian population

                                 Colorectal patients   General Slovenian population M (SD)   p-value                                           
  ------------------------------ --------------------- ------------------------------------- ------------- --------------- ----- ------------- --------------
  **Functional scoring scale**                                                                                                                 
  Physical functions             0                     100                                   83 (20.2)     87 (80--100)    197   91.8 (14)     **\< 0.001**
  Role functions                 0                     100                                   82.7 (26.8)   100 (67--100)   196   88.7 (20.1)   **0.002**
  Cognitive functions            0                     100                                   87.2 (18.1)   100 (83--100)   197   90.2 (16)     **0.021**
  Emotional functions            0                     100                                   83.4 (16.2)   83 (75--100)    197   82 (18.5)     0.239
  Social functions               0                     100                                   82.1 (24)     100 (67--100)   197   90.9 (17.3)   **\< 0.001**
  **Symptom scoring scale**                                                                                                                    
  Dyspnea                        0                     100                                   6.2 (16.1)    0 (0--0)        197   5.3 (15.3)    0.928
  Insomnia                       0                     100                                   22.4 (27.5)   0 (0--33)       197   19.8 (25.1)   0.182
  Loss of appetite               0                     100                                   5.6 (17.2)    0 (0--0)        195   5.3 (15.5)    0.791
  Nausea and vomiting            0                     50                                    2.9 (8.1)     0 (0--0)        195   3.3 (10.6)    0.524
  Constipation                   0                     100                                   13.2 (22.5)   0 (0--33)       196   6.9 (16.9)    **\< 0.001**
  Diarrhea                       0                     100                                   12.6 (22.7)   0 (0--33)       196   4.2 (13.6)    **\< 0.001**
  Fatigue                        0                     100                                   22.2 (22.2)   22 (0--33)      197   19.8 (19.8)   0.126
  Pain                           0                     100                                   13.8 (21.8)   0 (0--17)       195   14.5 (20.2)   0.633
  Financial impact of disease    0                     100                                   14.2 (26.6)   0 (0--33)       196   6.6 (17.5)    **\< 0.001**
  **Global health status**                                                                                                                     
  Global health status           17                    100                                   68.3 (20.5)   67 (50--83)     197   71.1 (21.4)   0.058

IQR = interquartile range; Max = maximum value; Me = median; Min = minimal value; SD = standard deviation; n = number of patients

When comparing QoL among CRC patients, statistically significant lower scores for cognitive and emotional functioning were detected in females. No other statistically significant differences between the sexes were detected ([Table 3](#j_raon-2019-0015_tab_003){ref-type="table"}).

###### 

Comparison of the scores for all the scales of the EORTC QLQ-C30 by sex.

                                 Male          Female          *p*-value                                      
  ------------------------------ ------------- --------------- ----------- ------------- --------------- ---- -----------
  **Functional scoring scale**                                                                                
  Physical functions             82.9 (19.1)   87 (80--100)    116         83.1 (21.8)   93 (80--100)    81   0.584
  Role functions                 84.1 (23.2)   100 (67--100)   115         80.7 (31.2)   100 (67--100)   81   0.982
  Cognitive functions            89.8 (15.2)   100 (83--100)   116         83.5 (21)     83 (67--100)    81   **0.034**
  Emotional functions            85.7 (14.9)   92 (75--100)    116         80 (17.5)     83 (75--92)     81   **0.008**
  Social functions               81.5 (22.7)   83 (67--100)    116         82.9 (25.8)   100 (67--100)   81   0.329
  **Symptom scoring scale**                                                                                   
  Dyspnea                        6 (16.2)      0 (0--0)        116         6.5 (16.1)    0 (0--0)        81   0.570
  Insomnia                       21.2 (26.9)   0 (0--33)       116         24.2 (28.4)   33 (0--33)      81   0.450
  Loss of appetite               4.3 (15.6)    0 (0--0)        115         7.5 (19.1)    0 (0--0)        80   0.115
  Nausea and vomiting            3.1 (8.7)     0 (0--0)        115         2.7 (7.3)     0 (0--0)        80   0.934
  Constipation                   13.6 (22.9)   0 (0--33)       115         12.7 (22)     0 (0--33)       81   0.903
  Diarrhea                       12.8 (22)     0 (0--33)       115         12.3 (23.8)   0 (0--33)       81   0.641
  Fatigue                        19.9 (21)     11 (0--33)      116         25.5 (23.5)   22 (0--33)      81   0.110
  Pain                           12.3 (19.8)   0 (0--17)       114         15.8 (24.4)   0 (0--22)       81   0.338
  Financial impact of disease    13.5 (26.7)   0 (0--33)       116         15.4 (26.5)   0 (0--33)       80   0.441
  **Global health status**                                                                                    
  Global health status           68.1 (21.4)   67 (50--83)     116         68.6 (19.3)   67 (50--83)     81   0.903

IQR = interquartile range; M = mean; Me = median; n = number of patients SD = standard deviation

When comparing the different age groups of the CRC patients (younger group 39--73 years, older group 74--92 years), statistically significant lower physical functioning scores were reported among the older patients. In addition, insomnia and dyspnea were more often reported among the older patients compared to the younger ones ([Table 4](#j_raon-2019-0015_tab_004){ref-type="table"}).

###### 

Comparison of the scores for all the scales of the EORTC QLQ-C30 by age groups

                                 Age 39--73 years   Age 74 --92 years   *p*-value                                      
  ------------------------------ ------------------ ------------------- ----------- ------------- --------------- ---- -----------
  **Functional scoring scale**                                                                                         
  Physical functions             87.5 (16.3)        93 (80--100)        98          78.6 (22.7)   87 (67--93)     99   **0.001**
  Role functions                 82.2 (28.7)        100 (67--100)       97          83.2 (24.9)   100 (67--100)   99   0.724
  Cognitive functions            89.3 (15)          100 (83--100)       98          85.1 (20.5)   100 (83--100)   99   0.268
  Emotional functions            85 (14.7)          83 (75--100)        98          81.7 (17.5)   83 (75--92)     99   0.218
  Social functions               84.7 (23.3)        100 (67--100)       98          79.5 (24.5)   83 (67--100)    99   0.069
  **Symptom scoring scale**                                                                                            
  Dyspnea                        3 (9.6)            0 (0--0)            98          9.4 (20.2)    0 (0--0)        99   **0.014**
  Insomnia                       16.6 (23.5)        0 (0--33)           98          28.2 (29.9)   33 (0--33)      99   **0.004**
  Loss of appetite               6.4 (18.3)         0 (0--0)            98          4.8 (15.9)    0 (0--0)        97   0.511
  Nausea and vomiting            2.9 (7.9)          0 (0--0)            98          2.9 (8.4)     0 (0--0)        97   0.993
  Constipation                   11.6 (22.6)        0 (0--33)           97          14.7 (22.4)   0 (0--33)       99   0.177
  Diarrhea                       10.8 (20.9)        0 (0--33)           97          14.4 (24.3)   0 (0--33)       99   0.286
  Fatigue                        20.9 (22.7)        22 (0--33)          98          23.6 (21.7)   22 (0--33)      99   0.228
  Pain                           11.5 (21.6)        0 (0--17)           98          16.1 (21.9)   0 (0--33)       97   0.061
  Financial impact of disease    18.7 (29.9)        0 (0--33)           98          9.8 (22)      0 (0--0)        98   0.025
  **Global health status**                                                                                             
  Global health status           69.8 (22.4)        75 (50--83)         98          66.8 (18.5)   67 (50--83)     99   0.132
                                                                                                                       

IQR = interquartile range; M = mean; Me = median; SD = standard deviation; n = number of patients

EORTC QLQ-CR29 Scoring scale {#j_raon-2019-0015_s_003_s_002}
----------------------------

Females more often reported bloating and hair loss. No other statistically significant differences in the rate of reporting other symptoms and in the scoring for mental health were found between the sexes ([Table 5](#j_raon-2019-0015_tab_005){ref-type="table"}).

###### 

Comparison of the scores for all the scales of the EORTC QLQ-CR29 by sex

                              Male          Female                                                   
  --------------------------- ------------- --------------- ----- ------------- --------------- ---- -----------
  **Symptom scoring scale**                                                                          
  Urinary frequency           29.4 (2.8)    33 (0--50)      115   28.1 (24.4)   33 (17--33)     81   0.670
  Urinary incontinence        9.1 (18.3)    0 (0--0)        116   9.1 (17.5)    0 (0--0)        80   0.941
  Dysuria                     4.6 (13.1)    0 (0--0)        115   2.4 (8.7)     0 (0--0)        81   0.266
  Abdominal pain              10.5 (16.7)   0 (0--33)       116   12.7 (19.4)   0 (0--33)       81   0.548
  Buttock pain                12.3 (22.2)   0 (0--33)       116   8.6 (20.3)    0 (0--0)        81   0.123
  Bloating                    18.9 (24.5)   0 (0--33)       116   25.4 (26)     33 (0--33)      81   **0.049**
  Blood & mucus in stool      3.4 (11.7)    0 (0--0)        116   3.5 (11.1)    0 (0--0)        81   0.939
  Dry mouth                   21 (25.2)     16.5 (0--33)    116   24.7 (28.8)   0 (0--33)       81   0.503
  Hair loss                   1.4 (6.7)     0 (0--0)        116   5.7 (15.5)    0 (0--0)        81   **0.010**
  Taste                       6 (16.2)      0 (0--0)        116   11.6 (24.3)   0 (0--0)        80   0.090
  **No stoma**                                                                                       
  Flatulence                  25.7 (29.8)   33 (0--33)      88    27.1 (29.1)   33 (0--33)      70   0.651
  Fecal incontinence          6.7 (18.2)    0 (0--0)        89    7.1 (16.8)    0 (0--0)        70   0.569
  Sore skin                   14 (22.4)     0 (0--33)       88    18.5 (25.1)   0 (0--33)       70   0.212
  Stool frequency             11.8 (18.3)   0 (0--17)       89    11.6 (16.4)   0 (0--17)       71   0.772
  Embarrassment               8.3 (18.3)    0 (0--0)        88    9.3 (20.6)    0 (0--0)        68   0.925
  **Mental health**                                                                                  
  Anxiety                     57.1 (29.1)   67 (33--67)     114   49.8 (26.6)   67 (33--67)     81   0.069
  Weight                      78.7 (28.1)   100 (67--100)   115   79.9 (29.2)   100 (67--100)   81   0.563
  Body image                  86.5 (20.2)   100 (78--100)   115   87.3 (21)     100 (78--100)   81   0.708

IQR = interquartile range; M = mean; Me = median; SD = standard deviation; n = number of patients

Compared to younger patients, older patients more often reported symptoms such as urinary frequency, urinary incontinence, and buttock pain. Older patients were also more concerned regarding their weight ([Table 6](#j_raon-2019-0015_tab_006){ref-type="table"}).

###### 

Comparison of the scores for all the scales of the EORTC QLQ-CR29 by age groups

                              Age 39--73 years   Age 74--92 years                                           
  --------------------------- ------------------ ------------------ ---- ------------- --------------- ---- -----------
  **Symptom scoring scale**                                                                                 
  Urinary frequency           24.7 (25.2)        17 (0--33)         97   33 (23.3)     33 (17--50)     99   **0.007**
  Urinary incontinence        5.9 (15.1)         0 (0--0)           98   12.4 (19.9)   0 (0--33)       98   **0.007**
  Dysuria                     3 (9.6)            0 (0--0)           98   4.4 (13.2)    0 (0--0)        98   0.607
  Abdominal pain              8.8 (14.6)         0 (0--33)          98   14.1 (20.2)   0 (0--33)       99   0.087
  Buttock pain                7.8 (20.2)         0 (0--0)           98   13.7 (22.3)   0 (0--33)       99   **0.007**
  Bloating                    19.6 (23.3)        0 (0--33)          98   23.5 (27.1)   33 (0--33)      99   0.404
  Blood & mucus in stool      4.1 (14)           0 (0--0)           98   2.8 (8.2)     0 (0--0)        99   0.938
  Dry mouth                   18.7 (24.2)        0 (0--33)          98   26.2 (28.7)   33 (0--33)      99   0.069
  Hair loss                   4.4 (14)           0 (0--0)           98   2 (7.9)       0 (0--0)        99   0.193
  Taste                       7.1 (17.4)         0 (0--0)           98   9.5 (22.4)    0 (0--0)        98   0.648
  **No stoma**                                                                                              
  Flatulence                  22.2 (27.3)        3 (0--33)          81   30.7 (31)     33 (0--33)      77   0.068
  Fecal incontinence          5.3 (14.4)         0 (0--0)           81   8.5 (20.4)    0 (0--0)        78   0.329
  Sore skin                   14.9 (23)          0 (0--33)          80   17 (24.4)     0 (0--33)       78   0.566
  Stool frequency             12.3 (18.2)        0 (0--17)          82   11.2 (16.7)   0 (0--17)       78   0.860
  Embarrassment               7.8 (17.7)         0 (0--0)           81   9.7 (21)      0 (0--0)        75   0.550
  **Mental health**                                                                                         
  Anxiety                     51.4 (30.1)        67 (33--67)        98   56.8 (26.1)   67 (33--67)     97   0.227
  Weight                      74.6 (30.8)        100 (67--100)      98   83.7 (25.4)   100 (67--100)   98   **0.031**
  Body image                  84.9 (22.8)        100 (78--100)      98   88.8 (17.7)   100 (78--100)   98   0.156

IQR = interquartile range; M = mean; Me = median; SD = standard deviation; n = number of patients

Discussion {#j_raon-2019-0015_s_004}
==========

QoL is a substantial factor when outcomes and effects of the disease on CRC patients after multimodal treatment are evaluated.[@j_raon-2019-0015_ref_013] In Slovenia, the evaluation of QoL in CRC patients is not yet systematically used. To the best of our knowledge, this is the first study evaluating QoL in CRC pa-

tients after surgery and comparing it with QoL for the general Slovenian population.

This study found no statistical differences in the reported global health score between CRC patients and the general Slovenian population. The results are comparable to other similar studies.[@j_raon-2019-0015_ref_006][@j_raon-2019-0015_ref_014]--[@j_raon-2019-0015_ref_017] On the other hand, compared to the general Slovenian population, our CRC patients reported poorer physical, cognitive, and social functioning. Moreover, they also more frequently reported symptoms such as constipation, diarrhea, and financial difficulties compared to the general Slovenian population. Similar results have been observed in other published studies.[@j_raon-2019-0015_ref_015],[@j_raon-2019-0015_ref_017] A comparable discovery was made by Rauch *et al*., in which patients more frequently reported lower physical functioning but also had greater levels of pain than the general population.[@j_raon-2019-0015_ref_014]

When comparing the responding and non-responding group of CRC patients, a higher rate of major postoperative complications was observed in the non-responding group. Postoperative complications that lead to reoperation, longer hospitalization, or stoma formation can greatly alter QoL in CRC patients. In our study, the reported satisfaction with QoL in the responding group may therefore be due to the lower rates of major post-operative complications. Nevertheless, patients in

the responding group were also younger (median age 73 years, compared to 75.5 years in the non-responding group, respectively; *p* = 0.016), which can also be an important factor contributing to reported better QoL in this group of patients. As determined in a study by Velenik *et al*., reported QoL in the general Slovenian population decreases with age.[@j_raon-2019-0015_ref_011]

In the general Slovenian population, a comparison of QoL between the sexes showed a statistically significant difference in reported physical functioning, which was poorer among females (*p* \< 0.000). No other statistically significant differences in functioning were reported.[@j_raon-2019-0015_ref_011] On the other hand, when comparing CRC patients by sex, female CRC patients more frequently reported lower cognitive and emotional functioning compared to males (*p* = 0.034 and 0.008, respectively). Females also more frequently reported bloating and hair loss, and the difference was statistically significant (*p* = 0.049 and 0.01, respectively). No other statistically significant differences were observed between the sexes.

Similar to our study, Adams *et al*. discovered that female CRC patients, compared to males, more often reported lower cognitive and emotional functioning, and also lower physical and social functioning.[@j_raon-2019-0015_ref_018] As the results show, female patients may need more emotional support following treatment. Therefore open discussion of the symptoms and suitable referrals for additional support or mental health treatments should be made during followups.[@j_raon-2019-0015_ref_019]

Reported QoL in the general Slovenian population is lower among the elderly.[@j_raon-2019-0015_ref_011] This phenomenon has also been reported by other European researchers.[@j_raon-2019-0015_ref_020]--[@j_raon-2019-0015_ref_022] Comparing QoL of different age groups shows lower physical functioning of older patients. (*p* = 0.001). Our results correlate with similar reports in the literature.[@j_raon-2019-0015_ref_023]--[@j_raon-2019-0015_ref_025] Statistically significant differences between age groups were discovered when reporting the frequency of symptoms of urinary frequency, urinary incontinence, and buttock pain. On the other hand, Japanese and American studies discovered better QoL in elderly patients.[@j_raon-2019-0015_ref_026],[@j_raon-2019-0015_ref_027] One can conclude that society and environment significantly influence individual evaluations of QoL.

Our study has limitations. First of all, the response rate was low (47.7%). For optimal results, the respond rate should be above 85%. This could be achieved by systematically distributing the questionnaire to CRC patients at follow-ups. Therefore, not only the feedback but also immediately addressing patients' key issues with possible additional referrals could be achieved. Another limitation is that the study was performed at a single tertiary center in Slovenia. For better results and optimal insight into QoL in CRC patients, a systematic multicenter study including all tertiary and regional centers in Slovenia should be carried out. The questionnaires should be given to CRC patients prior to surgery or neoadjuvant treatment, 1 month after surgery, and 1 and 5 years after treatment. In this way, comprehensive insight into QoL in CRC patients could be obtained, evaluating not only the influence of surgery but also the influence of neoadjuvant treatment on QoL in these patients.

Conclusions {#j_raon-2019-0015_s_005}
===========

This is the first Slovenian study comparing QoL in CRC patients with the general Slovenian population. The global health status of CRC patients in Slovenia is comparable to that of the general Slovenian population, but there is a significantly lower score on some of the QoL scales. For further research, a systematic multicenter study, including CRC patients from all Slovenian tertiary centers, should be performed with the aim of improving QoL for these patients with multidisciplinary follow-up treatment.
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